Y.D. More Investments Ltd Increases Stake in Kamada Ltd. (NASDAQ:KMDA)

Y.D. More Investments Ltd lifted its holdings in Kamada Ltd. (NASDAQ:KMDA) by 107.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 29,002 shares of the biotechnology company’s stock after purchasing an additional 15,000 shares during the quarter. Y.D. More Investments Ltd’s holdings in Kamada were worth $177,000 at the end of the most recent quarter.

Separately, Meitav Investment House Ltd. grew its holdings in shares of Kamada by 17.2% in the third quarter. Meitav Investment House Ltd. now owns 76,835 shares of the biotechnology company’s stock valued at $412,000 after purchasing an additional 11,284 shares in the last quarter. 20.38% of the stock is currently owned by institutional investors and hedge funds.

Kamada Trading Up 2.9 %

Shares of KMDA stock opened at $5.37 on Thursday. The stock has a market capitalization of $308.67 million, a price-to-earnings ratio of 35.80 and a beta of 1.05. Kamada Ltd. has a twelve month low of $4.08 and a twelve month high of $6.53. The stock has a fifty day simple moving average of $5.62 and a two-hundred day simple moving average of $5.47.

Kamada (NASDAQ:KMDA) last posted its quarterly earnings results on Wednesday, March 6th. The biotechnology company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.05 by $0.04. The business had revenue of $36.43 million during the quarter, compared to analyst estimates of $37.71 million. Kamada had a net margin of 5.81% and a return on equity of 5.66%. Research analysts predict that Kamada Ltd. will post 0.23 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on KMDA. StockNews.com upgraded Kamada from a “hold” rating to a “buy” rating in a research report on Thursday, January 4th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Kamada in a research note on Thursday, March 7th.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.